As well as the Ropren update, I am looking forward to Dr N...

As well as the Ropren update, I am looking forward to Dr N giving us trials info over many areas. We have a huge market as well with H Pyloria, we have markets everywhere and this little piggy wants to go to market. I want to make money and go wee wee wee all the way home!!!:) I wonder if they are progessing on the FDA front? can someone ask that please at the meeting????

"At least three additional production facilities are now planned for Russia to produce Bioeffective(R) A, Bioeffective(R) V and Bioeffective(R) R.

Beyond that, Solagran is looking to establish sites in Finland and in North America (potentially in either British Columbia or the Pacific Northwest).

An Executive Director has been appointed with primary responsibility for overseeing Solagran's global manufacturing capability.

Solagran's current strategy involves firstly building a strong market position in Russia with Ropren and Bioeffective(R) A, and then using Russia as a base to take Ropren and other Bioeffectives(R) to the world.

Chronic liver disease is a significant global problem. In the US, there are some 200,000 new cases, 300,000 hospitalisations and 30,000 deaths each year. Nevertheless, Solagran expects Ropren's very real potential to prevent and treat neurodegenerative disorders (including Alzheimer's and Parkinson's diseases), together with its ability to normalise cholesterol levels, will have a particularly significant impact in that country over time.

While the intention is to obtain registration for Ropren in the European Union prior to pursuing FDA registration in the US, there is a possibility that both could be done in parallel. Enquiries have already been received from a considerable number of individual patients and their families in Europe and the US in relation to the availability of Ropren to treat both liver disease and neurodegenerative disorders.

At the same time, trials in St Petersburg are progressing well with both the injectable and liposomal forms of Bioeffective(R) R, as well as with Bioeffectives(R) A, B and N.

Solagran's Directors consider the registration of Bioeffective(R) R and Ropren to be by far the most significant milestone achieved by Solagran since it listed in 2003. Achieving full registration for a new and multi-faceted pharmaceutical substance of natural origin in less than four years is truly outstanding - particularly given the amount of change that was occurring within the Russian Ministry of Health during the time that Solagran's application was being processed. Normally, the approval process would take at least twice as long.

Shortcutting this process was only possible due to the outstanding efficacy and safety of Ropren, the stature and reputation of Solagran's Executive Chairman Dr Vagif Soultanov within the Russian medical research community, the professionalism and dedication shown by Solagran's project team in Russia led by Professor Victor Roshchin.

Money made from Pine treew!!!!!